DMD # 71423

Introduction
Glioblastoma (GBM) is the most frequently diagnosed primary brain tumor in adults, with more than 10,000 patients affected each year in the US (CBTRUS, 2015) . Characterized by its invasiveness and aggressive progression, GBM, once diagnosed, presents a median survival of less than 2 years (Adamson et al., 2009) . Treatment options have remained limited with few advances or success in the past decades (Levin et al., 2015) , and despite an aggressive standard therapy that includes surgery, radiation and temozolomide, with the recent addition of bevacizumab at recurrence (Stupp et al., 2005; Friedman et al., 2009; Kreisl et al., 2009) , only 5% of patients survive longer than 5 years. Molecular as well as regional and microenvironmental heterogeneity of GBM can be invoked to explain this lack of improvement (Phillips et al., 2006; Cloughesy et al., 2014) . However, often overlooked is the significant challenge represented by the blood-brain barrier (BBB), constituted by tightly joined endothelial cells and efflux transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (de Vries et al., 2006) . These transporters further reduce the permeability and delivery of drugs to the brain and prevent them from reaching therapeutic concentrations. While disruption of the BBB often occurs in GBM (Oberoi et al., 2016) , and delivery of drugs to the tumor core has been shown (Hofer and Frei, 2007; Holdhoff et al., 2010) , infiltrative regions of compelling target for the treatment of high grade glioma. However, most, if not all, drugs acting on the PI3K pathway that have been tested, and have achieved disappointing results (Agarwal et al., 2011b) , are substrates of P-gp and/or BCRP, the two main efflux transporters expressed at the BBB. It is then expected that these compounds, including erlotinib (de Vries et al., 2012) , everolimus (Chu et al., 2009) , gefitinib (Agarwal et al., 2010) or lapatinib (Polli et al., 2009), will not be able to cross the BBB and are unlikely to maintain uniform and adequate concentrations throughout the brain. Fig. 1A) is a selective inhibitor of PI3K (p110α K i 2 nM) also able to potently inhibit mTOR (K i 70 nM) (Heffron et al., 2016) . This compound, possessing physicochemical properties optimized for brain penetration, was specifically developed as a potential treatment for GBM and is currently being evaluated in Phase I in patients with high grade glioma. was shown to inhibit the proliferation of several glioma cells in vitro with IC 50 ranging from 0.3 to 1.1 µM (U87: 0.74 µM, (Heffron et al., 2016) ; GS2: 0.61 µM, unpublished data). In addition, this compound was also able to inhibit the phosphorylation of Akt in U87 human glioma implanted as a subcutaneous xenograft in nude mice, leading to significant tumor growth inhibition (Heffron et al., 2016) .
GDC-0084 (
The goals of the studies presented here were to characterize the PI3K pathway modulation and the efficacy of GDC-0084 in orthotopic models of human GBM and to investigate the brain and tumor distribution of GDC-0084 in these intracranial tumor models.
This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 16, 2016 as DOI: 10.1124 at ASPET Journals on October 20, 2017 dmd.aspetjournals.org
Downloaded from
Materials and Methods
Chemicals
All Genentech compounds (>99% pure), including GDC-0084, [D6]GDC-0084 and pictilisib, were synthesized by Genentech, Inc. (South San Francisco, CA). All solvents used in analytical assays were purchased from Thermo Fisher Scientific (Watham, MA) and were of analytical or high-performance liquid chromatography grade. All other chemicals and reagents were purchased from Sigma-Aldrich (St Louis, MO) unless specified.
In Vitro Studies
Transport Assays in Cell Monolayers
Madin-Darby canine kidney (MDCK) cells expressing human P-gp, human BCRP or mouse Bcrp1 and LLC-PK1 cells transfected with mouse P-gp (mdr1a) were used to determine whether GDC-0084 was a substrate of these transporters. MDR1-MDCKI cells were licensed from the NCI (National Cancer Institute, Bethesda, MD) and Bcrp1-MDCKII, BCRP-MDCKII and Mdr1a-LLC-PK1 cells were obtained from the Netherlands Cancer Institute (Amsterdam, The Netherlands). For transport studies, cells were seeded on 24-well Millicell plates (Millipore, Billerca, MA) 4 days prior to use (polyethylene terephtalate membrane, 1 µm pore size) at a seeding density of 2.5x10 5 cells/mL (except for MDR1-MDCKI, 1.3x10 5 cells/mL). GDC-0084 was tested at 5 µM in the apical to basolateral (A-B) and basolateral to apical (B-A) directions.
The compound was dissolved in transport buffer consisting of Hank's balanced salt solution (HBSS) with 10 mM HEPES (Invitrogen Corporation, Grand Island, NY). Lucifer Yellow (Sigma-Aldrich, St. Louis, MO) was used as the paracellular and monolayer integrity marker.
GDC-0084 concentrations in the donor and receiving compartments were determined by LCThis article has not been copyedited and formatted. The final version may differ from this version. Where: dQ/dt = rate of compound appearance in the receiver compartment (fmol/sec);
A (cm 2 ) = Surface area of the insert; C 0 (µM) = Initial substrate concentration at T0.
The efflux ratio (ER) was calculated as (P app, B-A /P app, A-B ).
Determination of Plasma Protein and Brain Binding
GDC-0084 protein binding was determined in vitro, in mouse plasma (Bioreclamation, Inc., Hicksville, NY) by equilibrium dialysis using a RED device (Thermo Scientific, Rockford, IL)
as described previously (Salphati et al., 2012) . Incubations were performed in triplicate.
Parameters are presented as mean ± standard deviation (SD).
The binding of GDC-0084 to mouse brain was determined as described by Kalvass et al.(Kalvass et al., 2007) . Brain tissue was prepared and dialyzed as described previously (Salphati et al., 2012) . Following dialysis, tissues and buffer samples were analyzed as outlined for the plasma protein binding studies.
In vivo Studies
All studies performed were approved by the Institutional Animal Care and Use Committee at Genentech, Inc. (South San Francisco, CA) and are described in Table 1 .
Pharmacokinetic Study in Mouse
This article has not been copyedited and formatted. The final version may differ from this version. These antibodies cross-react between the human and the mouse proteins, allowing detection of pathway markers in mouse brain as well as in the intracranially implanted human tumors. The differences in marker levels between the treated and control mice were evaluated using the Student's t-test (Prism 5, GraphPad).
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Histology
Following completion of the imaging experiments, matrix coating was removed by rinsing the glass slide in 100% methanol for 30 seconds or until the entire matrix was visibly removed.
Tissue sections were stained utilizing a freshly prepared 0.5% cresyl violet staining solution (Chaurand et al., 2004) by submerging the glass slide for 30 seconds, then rinsed for an additional 30 seconds in two cycles of 100% ethanol. Microscope images were obtained on an Olympus BX51 (Tokyo, Japan) at 10x magnification and stitched using MicroSuite Analytical v3.0 software (Olympus, Tokyo, Japan). Subsequently, stained images were co-registered to the optical images in FlexImaging for visualization and annotation of tumor and non-tumor regions for the drug images.
Intra-Tumor and Healthy Brain Distribution
To assess drug distribution, imaging MALDI MS data from the U87 and GS2 tumor models were 
Efficacy Studies in Brain Tumor Models
The U-87 MG/M (U87) glioblastoma cancer cells (a Genentech variant of U-87 MG cells from American Type Culture Collection (Manassas, VA) and the GS 2 (GS2) glioblastoma cells (Gunther et al., 2008) were selected to test the efficacy of GDC-0084. These two models are PTEN-deficient, with the GS2 cell line having a copy number loss at the PTEN locus (Gunther et al., 2008) , and no detectable PTEN protein by western blot. (Carlson et al., 2011) This glioblastoma stem-like (GS) cell line, derived from an adult patient, long term survivor who had been subjected to two surgeries, radiation and chemotherapy, presents mutations in the TP53 gene, no amplification of the EGFR gene and forms spheres that grow semi-adherently in vitro (Gunther et al., 2008) . The identity of the two cell lines was confirmed by STR profiling (DNA Diagnostics Center) using cells within 5 passages of those utilized for in vivo studies. The U87 (250K) and GS2 (100K) tumor cells were injected via stereotaxic surgery into the right striatum in a volume of 3-5 µl. For each experiment, mice were randomized into groups of 10 to obtain comparable mean tumor volumes between treatment and control groups for each model.
Treatments were initiated at a time that ensured that the BBB had recovered from surgical disruption and tumors were expanding. Previous studies performed in our laboratories in intracranial models (and including sham surgery) indicated that the BBB had recovered from the disruption caused by the surgery after 7 days. Mice bearing intracranial U87 or GS2 xenografts were administered GDC-0084 (15 mg/kg), or vehicle (MCT) PO daily for 2 or 4 weeks, This article has not been copyedited and formatted. The final version may differ from this version. by ex vivo micro-computed tomography (micro-CT) imaging and T2 MRI for the GBM models U87 (on Day 14 of dosing) and GS2 (pre-dose and on Day 28 of dosing), respectively. The differences between treatment groups were evaluated using Student's t test in Prism (Prism 5, GraphPad). MRI was performed on a Varian 9.4T MRI system with a 30 mm quadrature volume coil. During the imaging, animals were kept under anesthesia with 2 % isoflurane in air. Body temperature was continuously monitored using a rectal probe and was maintained at 37° C by a heated-air flow system regulated by in-house LabVIEW controller software. A T2-weighted fast spin echo, multi-slice (FSEMS) sequence was used to detect lesions by MRI. 12-20 axial 0.5-0.8 mm-thick slices were acquired with a 20 x 20 mm field of view (FOV), and 128 x 128 matrix, zero-filled to 256 x 256 images. TR=3500-4000 ms, TE=9-10ms, ETL=8, k-zero=4, NEX=8.
Tumor volumes were calculated from the T2-weighted FSEMS images using an intensity threshold based region-growing tool in MRVision software. Brain sample preparation, micro-CT scanning, and image analysis for ex-vivo micro-CT imaging were performed as described previously (de Crespigny et al., 2008) .
In the studies conducted with the GS2 tumor-bearing mice, plasma and brains were also collected at the end of treatment to measure GDC-0084 concentrations and assess PI3K pathway modulation in the tumor. Each brain was dissected to separate the tumor from the healthy tissues.
Plasma and normal brains were processed and analyzed by LC-MS/MS. The GS2 tumors isolated This article has not been copyedited and formatted. The final version may differ from this version. from the brains were processed and the PI3K pathway markers pAkt, pS6 and p4EBP1 were measured as described previously.
The effects of GDC-0084 on the PI3K pathway in GS2 orthotopic tumors were also evaluated by immunohistochemistry following the last PO dose of GDC-0084 (15 mg/kg) to mice after the 4-week treatment. Brains were collected 2 hours following the last dose, after the animals had been anesthetized with pentobarbital, perfused first with heparinized phosphate-buffered saline and subsequently with 4% paraformaldehyde.
IHC for detection of pAkt and pPRAS40 with antibodies D9E and C77D7, respectively (Cell Signaling Technologies, Danvers, MA), was performed on 4µ thick paraffin-embedded tissue sections using a Discovery XT autostainer and CC1 standard antigen retrieval (Ventana Medical Systems; Tucson, AZ). Specifically bound primary antibody was detected using OmniMap detection (Ventana) followed by hematoxylin counterstain. The antibodies used react with the human and the mouse proteins, allowing detection of pathway markers in mouse brain as well as in the intracranially implanted human tumors.
Results
In Vitro Studies
Transport Studies in Transfected Cell Lines
The permeability and bidirectional transport of GDC-0084 were measured in transfected cell lines over-expressing human or mouse P-gp or BCRP. The apparent permeability (P app ) was high and comparable to that of metoprolol, the high P app marker used in the same experiments ( Table   2 ). The efflux ratios (P app, B-A /P app, A-B ) did not markedly differ from 1 in the MDCK or LLC-PK1 transfected cells ( Table 2 ), indicating that GDC-0084 was a poor substrate of these efflux transporters.
Plasma protein and Brain Tissues Binding
GDC-0084 binding to plasma proteins was low, with a free fraction (%) of 29.5 ± 2.7 (n=3) in CD-1 mouse plasma, when tested at 5 µM. Binding to brain tissues from CD-1 mice was higher, with a free fraction of 6.7% (± 1; n=3).
In Vivo Studies
Pharmacokinetics of GDC-0084 in Mouse
The plasma concentrations-time profile of GDC-0084 following a single oral dose (25 mg/kg) to mice is presented in Fig. 1B . Brain concentrations measured at 1 and 6 hours post-dose were similar to plasma levels. Total and free brain-to-free plasma ratios of approximately 1.4 and 0.4, respectively, were consistent at the two time points (Table 3) .
Modulation of pAkt and pS6 in Brain
This article has not been copyedited and formatted. The final version may differ from this version. Inhibition of the PI3K pathway was assessed in the brain of healthy mice through measurement of two markers, pAkt and pS6. Following a single oral dose of GDC-0084 (25 mg/kg), pAkt and pS6 levels were significantly lower than those detected in the control animals (Fig. 1C) .
Suppression of pAkt and pS6 reached 90% 1 hour post dose and stayed greater than 70% 6 hours after dosing (Fig. 1D ).
Brain and Tumor Distribution by MALDI Imaging
Distribution of GDC-0084 in the brain and intracranial U87 and GS2 tumors following administration of a single PO dose (15 mg/kg) was investigated by MALDI imaging. Brains were collected 1 hour post dose and images presented in Figure 2 show that GDC-0084 distributed readily and quite evenly throughout the brain, including in the GS2 ( Fig. 2A) and U87 (Fig. 2B) tumors. In addition, the homogeneity and pattern of distributions of GDC-0084 in the tumors and non-tumored regions of the brains were further analyzed. In order to assess in a more quantitative manner, less prone to visual bias, the homogeneity of the brain distribution, the intensity of each pixel (signal) was extracted in the entire tumor region or in the whole nontumored, healthy area, of the brains. The frequency of signal intensities (frequency of pixel intensities), binned by increment of 0.1 as described in the Methods, appeared to follow a normal distribution in healthy brain, superimposed (mean pixel intensity 0.54) to that observed in U87 tumors ( Fig. 3A ; mean pixel intensity 0.54). The similar mean pixel intensities in the two regions of the brain along with the superimposable Gaussian distributions indicated that the compound was able to reach the tumor and the non-diseased brain to a similar extent. A Gaussian distribution of signals was observed as well in GS2 tumors (Fig. 3B ), also indicating a homogeneous tumor penetration, however with a slightly lower mean pixel intensity (0.34 vs.
This article has not been copyedited and formatted. The final version may differ from this version. 0.55), suggesting an overall lower GDC-0084 concentration in GS2 tumors than in normal brain.
Comparisons of the GDC-0084 signal homogeneity in non-tumored brain regions between the U87 and GS2 tumor-bearing mice showed identical distribution ( Fig. 3C ) and mean pixel intensities, confirming the reproducible and consistent brain penetration properties of GDC-0084. Similar results were obtained in brains collected at 6 hours post dose. Furthermore, to contrast the distribution of GDC-0084 to that of a non-brain penetrant compound, MALDI images previously obtained with pictilisib in the U87 tumor model (Salphati et al., 2014) were re-analyzed by extracting pixel intensity frequencies as described here. While signal intensities in the U87 tumor for GDC-0084 could be fit to a Gaussian curve, signals from pictilisb were concentrated in the low intensity bins, with a distribution that appeared more heterogeneous (Fig.   3D ). This can be interpreted as poor brain penetration, with localized hot spots of signal, due to leaky BBB.
Efficacy in Brain Tumor Models
The efficacy of GDC-0084 was tested in the U87 and GS2 intracranial models. GDC-0084 was administered PO at 15 mg/kg daily for 2 and 4 weeks to U87 and GS2 tumor-bearing mice, respectively. The effect of the treatment on the U87 and GS2 tumor volumes was assessed at the end of the dosing period. Images of U87 tumor obtained by micro-CT are presented in Figure   4A . The U87 tumor volumes were reduced by approximately 70%, when compared to the vehicle control, (Fig. 4B) following treatment with GDC-0084. Similarly, the GS2 tumors measured by MRI (Fig. 4C ) in the treated mice were significantly (p<0.01) smaller (≈40%) than those in the control group (Fig. 4D ). Plasma and healthy brain concentrations of GDC-0084 were measured at the end of the study in the GS2 tumor-bearing mice and are presented along with brain-toThis article has not been copyedited and formatted. The final version may differ from this version. Table 4 . Brain concentrations in the normal part of the brain and brain-to-plasma ratios were comparable to those obtained previously (Table 3) . Modulation of the PI3K pathway in the GS2 tumors was assessed by western blot at the end of the dosing period, 2 and 8 hours after the final administration of GDC-0084 (Fig. 5A) . Levels of pAkt were significantly reduced at 2 and 8 hours, by 90 and 70%, respectively. Suppression of pS6 and p4EBP1 was less pronounced at 2 hours, reaching 35 and 43%, respectively. These two markers were back to baseline levels 8 hours post-dose (Fig. 5B ). In addition, inhibition of the PI3K pathway was also measured at tumor cell level by immunohistochemistry. The tissue was probed with antibodies against the PI3K pathway markers pAkt and pPRAS40. GDC-0084 caused a marked reduction in staining when compared to the vehicle-treated animal (Fig. 5C ), confirming inhibition of the pathway in the tumor.
Discussion
The PI3K pathway is altered in more than 80% of patients diagnosed with GBM. However, repeated failures of PI3K inhibitors in clinical trials may call into question the validity of this target or the ability to reach it for therapeutic benefit (Nichol and Mellinghoff, 2015) .
In order to ensure delivery of the drug to its target and address one of the obstacles to effective treatment, the PI3K inhibitor GDC-0084 was specifically optimized to cross the BBB, while maintaining adequate potency (p110α K i 2 nM; mTOR K i 70 nM) and selectivity (Heffron et al., 2016) with the treatment of GBM and PI3K-dependent brain tumors as the primary objective. In vitro studies in MDCK and LLC-PK cells over-expressing human or mouse P-gp or BCRP indicated that GDC-0084 was not a good substrate of these two efflux transporters (Table 2) , which limit the brain penetration of many compounds (Agarwal et al., 2011a) . These in vitro results suggesting that GDC-0084 brain penetration would not be hindered by these transporters were consistent with data obtained in vivo in mice showing that GDC-0084 was able to cross the BBB following PO administration (25 mg/kg), and reach free brain concentrations greater than pAkt inhibition IC 50 estimated in PC3 cells (0.13 µM; PTEN-null cells used in our program to test and select PI3K inhibitors) (Heffron et al., 2016) . These levels of free drug (i.e., available to interact with the PI3K) at the target site (brain) achieved significant pathway suppression up to 6 hours post-dose (Fig. 1) . The total brain-to-plasma ratio exceeded 1 and the ratio of free concentrations in brain and plasma was 0.4 (Table 3 ). For drug passively permeating the BBB, the equilibrium theory of free drug applies (Tillement et al., 1988) , and the ratio of unbound concentrations in the brain and plasma (C u,br /C u,p ) is expected to equal (or approach) 1. further analyses by MALDI imaging confirmed that GDC-0084 was able to distribute uniformly throughout the brain and tumors in the two orthotopic models of GBM tested (Fig. 2) , the U87
and GS2 glioma cells. The U87 cell line is a widely used and characterized glioma model (Clark et al., 2010 ) that grows adherently when cultured and forms well-delineated tumors when implanted as intracranial xenograft. The GS2 cells grow in vitro as neurosphere and develop more diffusive tumors in the brain (Gunther et al., 2008) . While these two models present striking differences in their BBB status (intact vs. disrupted) (Salphati et al., 2014) , the analysis of drug signal intensity revealed a Gaussian distribution, reflective of homogeneous penetration of GDC-0084 in the U87 and GS2 tumors as well as in non-tumor regions of the brain (Fig. 3) , independent of the local variations in BBB integrity. In addition, in the U87 tumor model, mean pixel intensities (related to compound concentration) were similar in the tumor and in the healthy part of the brain, suggesting undifferentiated distribution in these two areas (Fig. 3A) . In the GS2 tumors, signal intensities also appeared to follow a normal distribution, consistent with homogeneous penetration of the compound. The mean pixel intensity was nevertheless slightly lower in the tumor than in the non-tumor region (0.37 vs. 0.55). This weaker signal in the GS2 tumor may be caused by lower tumor vascularization, which could limit the diffusion of GDC-0084. The nearly superimposed frequencies of signal intensities in the healthy brain region of mice bearing either GS2 or U87 tumors underscore the consistency and reproducibility of GDC-0084 brain penetration (Fig. 3C) . In contrast, reanalysis of data previously obtained with the PThis article has not been copyedited and formatted. The final version may differ from this version. Table 2 ) and non-brain penetrant compound pictilisb (Salphati et al., 2014) showed heterogeneous (non Gaussian) intratumor distribution of pixel intensities (Fig. 3D) , 2006; Pitz et al., 2011) , while these drugs had minimal therapeutic effects. Similarly, high levels of erlotinib were shown to co-localize with the contrast-enhancing regions of brain metastases (Weber et al., 2011) .
The potent inhibition of the PI3K pathway in the brain, as well as the distribution in healthy tissues and brain tumor, suggested that GDC-0084 could be efficacious in orthotopic models of GBM. Studies in the U87 and GS2 models showed that GDC-0084 could significantly reduce tumor volumes, compared to the vehicle control. While promising, the findings in the U87 tumors were not unexpected as this model presents a disrupted BBB and can be sensitive to compounds with limited brain distribution (Carcaboso et al., 2010; Salphati et al., 2012) . This (Salphati et al., 2014) and recapitulates better the invasive regions of GBM. In that model, GDC-0084 administration significantly reduced tumor volume, when compared to vehicle treatment, and led to marked suppression of the PI3K pathway (Fig. 5) , assessed by western blot and IHC (Fig. 5C ). However, this significant efficacy was less pronounced than in the U87 model, despite comparable in vitro potency against the two cell lines. This may be attributed to the slightly lower concentration of GDC-0084 in the GS2 tumor suggested by MALDI imaging, or could also indicate that pathways other than PI3K contribute to the growth of these tumors. This hypothesis may only be tested with the combination of agents able, like GDC-0084, to cross the BBB and distribute throughout the brain. When considering the genetic heterogeneity of GBM, such combination therapies may be necessary to achieve optimal efficacy.
Multiple studies and a recent symposium have emphasized the role of the BBB and efflux transporters (or blood-tumor barrier) in limiting the therapeutic effects of most targeted drugs evaluated in GBM clinical trials (Agarwal et al., 2011b; Levin et al., 2015; Oberoi et al., 2016) .
While it is not the only challenge, it still appears to be an "underappreciated obstacle" (Mason, 2015) to optimal GBM treatment. In addition, maintaining or improving potency against pathways or targets involved in GBM, as well as ensuring that adequate free concentrations are reached in the brain (Smith et al., 2010) are also key elements in the optimization of potential drugs. The PI3K inhibitor GDC-0084 was purposedly designed to cross an intact BBB and distribute throughout the brain. It is being evaluated in patients, and exposures reached at tolerated doses are consistent with those associated with efficacious doses in mouse models.
While brain penetrance is a necessary but not sufficient attribute, this compound may provide a This article has not been copyedited and formatted. The final version may differ from this version. 
